Citations

Clear

3314 citation(s) found for "Yu, Alexander".

Bayesian Change Point Detection for Mixed Data with Missing Values
Storlie, Curtis B. , Murph, Alexander C.

Mayo Clinic

2022 IEEE 10th International Conference on Healthcare Informatics (ICHI) | September 8, 2022 | Volume: No volume available | Issue: No issue available | Pages: 499-501

10.1109/ichi54592.2022.00087 Get It

A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor–Positive Ovarian Cancer (Study 006)
Tanyi, János L. , Randall, Leslie M. , Chambers, Setsuko K., Butler, Kristina , Langstraat, Carrie , Han, Ernest , Chon, Hye Sook, Morgan, Mark A. , Powell, Matthew A. , Tseng, Jill, Lopez, Alexis S., Wenham, Robert M. , Butler, Kristina A., Langstraat, Carrie L , Han, Ernest S , Morgan, Mark A , Powell, Matthew A , Wenham, Robert M , Winer, Ira Seth , Vahrmeijer, Alexander L.

Mayo Clinic

Journal of Clinical Oncology | September 7, 2022 | Volume: 41 | Issue: 2 | Pages: 276-284

10.1200/jco.22.00291 | PMID 36070540 Get It

PURPOSE The adjunctive use of intraoperative molecular imaging (IMI) is gaining acceptance as a potential means to improve outcomes for surgical resection of targetable tumors. This confirmatory study examined the use of pafolacianine for real-time detection of folate receptor–positive ovarian cancer. METHODS This phase III, open-label, 11-center study included subjects with known or suspected ovarian cancer, scheduled to undergo cytoreductive surgery. The objectives were to confirm safety and efficacy of pafolacianine (0.025 mg/kg IV), given ≥ 1 hour before intraoperative near-infrared imaging to detect macroscopic lesions not detected by palpation and normal white light. RESULTS From March 2018 through April 2020, 150 patients received a single infusion of pafolacianine (safety analysis set); 109 patients with folate receptor–positive ovarian cancer comprised the full analysis set for efficacy. In 33.0% of patients (95% CI, 24.3 to 42.7; P < .001), pafolacianine with near-infrared imaging identified additional cancer on tissue not planned for resection and not detected by white light assessment and palpation, exceeding the prespecified threshold of 10%. Among patients who underwent interval debulking surgery, the rate was 39.7% (95% CI, 27.0 to 53.4; P < .001). The sensitivity to detect ovarian cancer was 83%, and the patient false-positive rate was 24.8%. Investigators reported achieving complete R0 resection in 62.4% (68 of 109) of patients. Drug-related adverse events were reported by 30% of patients (45 of 150) and most commonly included nausea, vomiting, and abdominal pain. No drug-related serious adverse events or deaths were reported. CONCLUSION This phase III study of pafolacianine met its primary efficacy end point, identifying additional cancers not otherwise identified or planned for resection. Pafolacianine may offer an important real-time adjunct to current surgical approaches for ovarian cancer.
Exercise Training Attenuates Pulmonary Inflammation In High-fat High-carbohydrate Induced NAFLD
Johnson, Bruce D. , Watt, Kymberly D. , Han, Tae‐Kyung, Kim, Chul-Ho, Cho, Jinkyung , Niven, Alexander S. , Kim, Chul-Ho

Mayo Clinic

Medicine & Science in Sports & Exercise | September 6, 2022 | Volume: 54 | Issue: 9S | Pages: 652-652

10.1249/01.mss.0000883212.78575.55 Get It

Resuscitation code status among emergency department patients: decision support education video pilot study
Finch, Alexander S , Stanich, Jessica A. , Spadaro, Maria J, Tschautscher, Craig F., Walker, Laura , Brauer, Caitlin E. Loprinzi, Finch, Alexander S. , Tschautscher, Craig F.

Mayo Clinic

BMJ Supportive & Palliative Care | September 5, 2022 | Volume: 14 | Issue: e1 | Pages: e492-e495

10.1136/spcare-2022-003538 Get It

Objectives Establishment of code status can be challenging in the acute care setting. The primary objective of the present study was to evaluate whether patients or their surrogate decision-makers were comfortable watching an educational video about resuscitation. Methods This interventional pilot study involved a pre- and a postintervention survey of a convenience sample of emergency department (ED) patients who were admitted to the hospital. The study was conducted at an academic level-1 trauma centre within the normal flow of patient care over 4 months in 2017. Results In total, 50 patients enrolled in the study. Among them, 82% were ‘very comfortable’ and 14% were ‘moderately comfortable’ watching the video. Overall, 61% of respondents were ‘very comfortable’ recommending the video to others. Watching the video resulted in a change in code status for 9 patients. Conclusions Our results indicate that patients felt comfortable watching the video and recommending the video for further use. Watching the video did not result in a change in code status for most patients in this study. The study results indicate that a standardised patient education video on resuscitation code status was acceptable to patients and their family members and has potential for increased use in the ED.
Vasculogenic gene therapy: No role for revitalization of structural bone allografts
Rezaie, Elisa S., Visser, Noortje J., Berg, Catherine van den, Bishop, Allen T. , van den Berg, Catherine, Bishop, Allen T , Shin, Alexander Y.

Mayo Clinic

Journal of Orthopaedic Research | September 5, 2022 | Volume: 41 | Issue: 5 | Pages: 1014-1021

10.1002/jor.25438 | PMID 36058614 Get It

AbstractSegmental bone defects are often performed with cryopreserved allografts. They provide immediate stability, but risk nonunion, infection and late stress fracture. Improving the rate and extent of bone revitalization may improve results. Angiogenesis from surgically placed arteriovenous (AV) bundles improves bone blood flow and vitality in cryopreserved rat femora, augmented by vasculogenic growth factors. This study tests the same principal in Yucatan mini‐pigs with a tibial diaphyseal defect, combining surgical angiogenesis with angiogenic gene therapy within cryopreserved orthotopically‐placed allografts. Tibial diaphyseal defects were reconstructed with cryopreserved allografts and rigid internal fixation in 16 mini pigs. Half of the cranial tibial AV bundles placed within the allograft medullary canal were transfected with an adeno‐associated virus containing vascular endothelial growth factor (VEGF) and platelet‐derived growth factor (PDGF) genes (AAV9.VEGF.PDGF). Bone remodeling, angiogenesis, and allograft healing were assessed. During the postoperative survival period 5 of 8 transfected animals developed cutaneous benign vascular lesions at sites remote from the operated hindlimb, causing excessive bleeding. Within the allograft, both medullary (p = 0.013) and cortical (p = 0.009) vascular volumes were higher and vessels more mature than nontransfected allografts. Bone turnover (p = 0.013), bone mineralization (p = 0.018), bone healing (p = 0.008) and graft incorporation (p = 0.006) were all significantly higher in the gene therapy group. In a large animal tibial defect model, gene therapy of implanted AV bundles improved revascularization, remodeling and healing of cryopreserved allografts used for limb reconstruction. However, benign vascular lesions causing excessive bleeding developed in 5 out of 8 pigs transfected with AAV containing genes for VEGF and PDGF. This unforeseen complication makes vasculogenic gene therapy unacceptable for clinical use.
Inclusion of a core patient-reported outcomes battery in adolescent and young adult cancer clinical trials
Roth, Michael , Parsons, Susan K. , Ganz, Patricia A. , Wagner, Lynne I. , Alexander, Sarah , Bingen, Kristin , Cella, David , Henry, N. Lynn , Indelicato, Daniel J. , Johnson, Rebecca H. , Miller, Tamara P. , Rosenberg, Shoshana M. , Thanarajasingam, Gita , Roth, Michael E , Thanarajasingam, Gita , Reeve, Bryce B. , Salsman, John M , Wagner, Lynne , Henry, N Lynn , K Parsons, Susan , Indelicato, Daniel J , Hinds, Pamela S. , Bober, Sharon L. , Brackett, Julienne , Schmitz, Kathryn H.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 2, 2022 | Volume: 115 | Issue: 1 | Pages: 21-28

10.1093/jnci/djac166 | PMID 36266760 Get It

Abstract Disparities in care, treatment-related toxicity and health-related quality of life (HRQoL) for adolescents and young adults (AYAs, aged 15-39 years) with cancer are under-addressed partly because of limited collection of patient-reported outcomes (PROs) in cancer clinical trials (CCTs). The AYA years include key developmental milestones distinct from younger and older patients, and cancer interrupts attainment of critical life goals. Lack of consensus on a standardized approach to assess HRQoL and treatment-related toxicity in AYA CCTs has limited the ability to improve patient outcomes. The National Cancer Institute’s Clinical Trials Network AYA PRO Task Force was assembled to reach consensus on a core set of PROs and foster its integration into AYA CCTs. Eight key considerations for selecting the core PRO AYA battery components were identified: relevance to AYAs; importance of constructs across the age continuum; prioritization of validated measures; availability of measures without licensing fees; availability in multiple languages; applicability to different cancer types and treatments; ability to measure different HRQoL domains and toxicities; and minimized burden on patients and sites. The Task Force used a modified Delphi approach to identify key components of the PRO battery. The Patient-Reported Outcomes Measurement Information System (PROMIS) and the PRO Common Terminology Criteria for Adverse Events Measurement System met all criteria and were selected to assess HRQoL and treatment toxicity, respectively. Investigators are rapidly incorporating the recommendations of the Task Force into AYA trials. Inclusion of a standardized assessment of HRQoL and treatment toxicities in AYA CCTs is a vital first step to develop interventions to improve health outcomes for AYAs diagnosed with cancer.
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
Nagalo, Bolni Marius , Zhou, Yumei , Loeuillard, Emilien , Dumbauld, Chelsae, Barro, Oumar, Elliott, Natalie , Baker, Alexander T. , Arora, Mansi , Meurice, Nathalie , Aslam, Faaiq , Gabere, Musa , Basnakian, Alexei G. , Simões, Camila , Cannon, Martin J. , Buetow, Kenneth H. , Barrett, Michael T. , Duda, Dan G. , Jacobs, Bertram , Vile, Richard G. , Barry, Michael A. , Roberts, Lewis R. , Loeuillard, Emilien J, Elliott, Natalie , Bogenberger, James M. , Petit, Joachim, Uson, Pedro L S , Raupach, Elizabeth, Chamcheu, Jean Christopher , Duda, Dan G , Ilyas, Sumera Irie , Roberts, Lewis R , Barry, Michael A , Nagalo, Bolni , Baker, Alexander , Aslam, Faaiq N , Petit, Joachim L. , Usón, Pedro Luiz Serrano , Raupach, Elizabeth A. , Post, Steven R. , Ilyas, Sumera I. , Borad, Mitesh J.

Mayo Clinic

Hepatology | September 2, 2022 | Volume: 77 | Issue: 6 | Pages: 1943-1957

10.1002/hep.32769 | PMID 36052732 Get It

Background: Morreton virus (MORV) is an oncolytic Vesiculovirus , genetically distinct from vesicular stomatitis virus (VSV). Aim: To report that MORV induced potent cytopathic effects (CPEs) in cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC) in vitro models. Approach and Results: In preliminary safety analyses, high intranasal doses (up to 10 10 50% tissue culture infectious dose [TCID 50 ]) of MORV were not associated with significant adverse effects in immune competent, non–tumor‐bearing mice. MORV was shown to be efficacious in a Hep3B hepatocellular cancer xenograft model but not in a CCA xenograft HuCCT1 model. In an immune competent, syngeneic murine CCA model, single intratumoral treatments with MORV (1 × 10 7 TCID 50 ) triggered a robust antitumor immune response leading to substantial tumor regression and disease control at a dose 10‐fold lower than VSV (1 × 10 8 TCID 50 ). MORV led to increased CD8 + cytotoxic T cells without compensatory increases in tumor‐associated macrophages and granulocytic or monocytic myeloid‐derived suppressor cells. Conclusions: Our findings indicate that wild‐type MORV is safe and can induce potent tumor regression via immune‐mediated and immune‐independent mechanisms in HCC and CCA animal models without dose limiting adverse events. These data warrant further development and clinical translation of MORV as an oncolytic virotherapy platform.
The prevalence and clinical outcomes of microangiopathic hemolytic anemia in patients with biopsy‐proven renal thrombotic microangiopathy
Bhutani, Gauri , Leung, Nelson , Said, Samar M. , Valeri, Anthony M., Fidler, Mary E., Alexander, Mariam P., Cornell, Lynn D. , Nasr, Samih H. , Leung, Nelson , Cornell, Lynn , Astor, Brad C.

Mayo Clinic

American Journal of Hematology | August 28, 2022 | Volume: 97 | Issue: 11 | Pages: No page available

10.1002/ajh.26705 | PMID 36054780 Get It

Critical Care Cardiology Trials Network (CCCTN): a cohort profile
Metkus, Thomas S. , Baird-Zars, Vivian M., Alfonso, Carlos E., Alviar, Carlos L. , Barsness, Gregory W. , Bertić, Mia , Bohula, Erin A. , Burke, James A. , Burstein, Barry , Cooper, Howard A., Daniels, Lori B. , Goldfarb, Michael , Katz, Jason N. , Keeley, Ellen C. , Keller, Norma, Kenigsberg, Benjamin B. , Kontos, Michael C. , Lawler, Patrick R. , Leibner, Evan , Menon, Venu , Miller, P. Elliott , Newby, L. Kristin , O’Brien, Connor , Papolos, Alexander , Pierce, Matthew J, Prasad, Rajnish, Pisani, Barbara , Smith, Timothy D., Snell, R. Jeffrey, So, Derek , Ternus, Bradley , Teuteberg, Jeffrey J. , Zakaria, Sammy , Goldfarb, Michael , Pierce, Matthew , Fordyce, Christopher B , Goldfarb, Michael , Solomon, Michael A , van Diepen, Sean , Goldfarb, Michael , Lawler, Patrick , Daniels, Lori B , Bohula, Erin A , Zakaria, Sammy , O'Brien, Connor G , Pierce, Matthew J , Barnett, Christopher F. , Berg, David D. , Burke, James, Chaudhry, Sunit‐Preet , Fordyce, Christopher B. , Ghafghazi, Shahab , Kwon, Younghoon, Liu, Shuangbo , Prasad, Rajnish, Potter, Brian J , Roswell, Robert O. , Sinha, Shashank S , Shah, Kevin S , Solomon, Michael A. , Diepen, Sean van , Morrow, David A.

Mayo Clinic

European Heart Journal - Quality of Care and Clinical Outcomes | August 27, 2022 | Volume: 8 | Issue: 7 | Pages: 703-708

10.1093/ehjqcco/qcac055 | PMID 36029517 Get It

AbstractAimsThe aims of the Critical Care Cardiology Trials Network (CCCTN) are to develop a registry to investigate the epidemiology of cardiac critical illness and to establish a multicentre research network to conduct randomised clinical trials (RCTs) in patients with cardiac critical illness.Methods and resultsThe CCCTN was founded in 2017 with 16 centres and has grown to a research network of over 40 academic and clinical centres in the United States and Canada. Each centre enters data for consecutive cardiac intensive care unit (CICU) admissions for at least 2 months of each calendar year. More than 20 000 unique CICU admissions are now included in the CCCTN Registry. To date, scientific observations from the CCCTN Registry include description of variations in care, the epidemiology and outcomes of all CICU patients, as well as subsets of patients with specific disease states, such as shock, heart failure, renal dysfunction, and respiratory failure. The CCCTN has also characterised utilization patterns, including use of mechanical circulatory support in response to changes in the heart transplantation allocation system, and the use and impact of multidisciplinary shock teams. Over years of multicentre collaboration, the CCCTN has established a robust research network to facilitate multicentre registry-based randomised trials in patients with cardiac critical illness.ConclusionThe CCCTN is a large, prospective registry dedicated to describing processes-of-care and expanding clinical knowledge in cardiac critical illness. The CCCTN will serve as an investigational platform from which to conduct randomised controlled trials in this important patient population.
Glutamate Neurotoxicity and Destruction of the Blood–Brain Barrier: Key Pathways for the Development of Neuropsychiatric Consequences of TBI and Their Potential Treatment Strategies
Gruenbaum, Benjamin F. , Frenkel, Amit , Boyko, Matthew , Frenkel, Amit , Boyko, Matthew , Gruenbaum, Benjamin Fredrick , Zlotnik, Alexander Anatolievich , Fleidervish, Ilya A.

Mayo Clinic

International Journal of Molecular Sciences | August 25, 2022 | Volume: 23 | Issue: 17 | Pages: 9628

10.3390/ijms23179628 | PMID 36077024 Get It

Traumatic brain injury (TBI) is associated with significant cognitive and psychiatric conditions. Neuropsychiatric symptoms can persist for years following brain injury, causing major disruptions in patients’ lives. In this review, we examine the role of glutamate as an aftereffect of TBI that contributes to the development of neuropsychiatric conditions. We hypothesize that TBI causes long-term blood–brain barrier (BBB) dysfunction lasting many years and even decades. We propose that dysfunction in the BBB is the central factor that modulates increased glutamate after TBI and ultimately leads to neurodegenerative processes and subsequent manifestation of neuropsychiatric conditions. Here, we have identified factors that determine the upper and lower levels of glutamate concentration in the brain after TBI. Furthermore, we consider treatments of disruptions to BBB integrity, including repairing the BBB and controlling excess glutamate, as potential therapeutic modalities for the treatment of acute and chronic neuropsychiatric conditions and symptoms. By specifically focusing on the BBB, we hypothesize that restoring BBB integrity will alleviate neurotoxicity and related neurological sequelae.